BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 9342117)

  • 1. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
    Runge VM; Lee C; Iten AL; Williams NM
    Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging in a spinal abscess model. Preliminary report.
    Runge VM; Williams NM; Lee C; Timoney JF
    Invest Radiol; 1998 Apr; 33(4):246-55. PubMed ID: 9556750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
    Runge VM
    Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis.
    Runge VM; Williams NM
    Invest Radiol; 1998 Jan; 33(1):45-50. PubMed ID: 9438509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging of experimental pyelonephritis in rabbits.
    Runge VM; Timoney JF; Williams NM
    Invest Radiol; 1997 Nov; 32(11):696-704. PubMed ID: 9387058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detectability of early brain meningitis with magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM; Lee C; Timoney JF; Young AB
    Invest Radiol; 1995 Aug; 30(8):484-95. PubMed ID: 8557515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
    Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
    Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR imaging of the myocardium using nonionic contrast medium: signal-intensity changes in patients with subacute myocardial infarction.
    Dulce MC; Duerinckx AJ; Hartiala J; Caputo GR; O'Sullivan M; Cheitlin MD; Higgins CB
    AJR Am J Roentgenol; 1993 May; 160(5):963-70. PubMed ID: 8470611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose applications of gadolinium chelates in magnetic resonance imaging.
    Runge VM; Kirsch JE; Thomas GS
    Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the temporal evolution of acute spinal cord injury.
    Runge VM; Wells JW; Baldwin SA; Scheff SW; Blades DA
    Invest Radiol; 1997 Feb; 32(2):105-10. PubMed ID: 9039583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
    Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
    Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.